Results 131 to 140 of about 182,433 (270)

Forest plot showing the achievement of SVR in CHC patients with low baseline HCV RNA treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.

, 2014
Forest plot showing the achievement of SVR in CHC patients with low baseline HCV RNA treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.
Caterina Sagnelli (430094), Evangelista Sagnelli (430095), Nicola Coppola (430089), Italo F. Angelillo (300520), Mariantonietta Pisaturo (430090)   +4 more
core   +1 more source

Some safety aspects of a new russian pegylated interferon-A medication “ALGERON” (phase 1 clinical trial)

RUDN Journal of Medicine, 2014
Treatment of hepatitis C is one of the most acute international healthcare problems. High standard in management of patients with HCV virus is combined therapy with pegylated interferon-a plus ribavirin.
A I Tukach, S B Fitilev, I I Shkrebniova, A V Vozzhaev, V A Yakushev, R A Ivanov, Yu N Lin’kova, T V Chernovskaya   +7 more
doaj  

Early viral kinetics and response to treatment in a hepatitis C virus genotype 5 infected patient

Clinics and Practice, 2011
Genotype 5 hepatitis C has been poorly studied despite its worldwide spread. We have analyzed the early kinetics of genotype 5 hepatitis C virus RNA during pegylated interferon/ribavirin treatment in a 59-year-old man with active liver necroinflammatory ...
Emanuele Durante-Mangoni, Domenico Iossa, Umberto Malgeri   +2 more
doaj   +1 more source

From Molecular Targets to Advanced Delivery Systems: Aptamers for Precision Ocular Therapeutics

Advanced Therapeutics, Volume 9, Issue 10, October 2026.
Aptamer‐based strategies are revolutionizing ocular disease management through highly specific molecular recognition of disease specific molecular targets. This review systematically integrates therapeutic aptamer sequences, diagnostic aptasensor platforms, and targeted delivery strategies, highlighting design principles, ocular bioavailability ...
Minal Thacker, Ka‐Ying Wong, Liping Zhou, Man‐Sau Wong, Juewen Liu   +4 more
wiley   +1 more source

Test system for the detection of binding antibodies to interferon beta-1a for clinical use

Биопрепараты: Профилактика, диагностика, лечение, 2018
Test system for determining the presence of binding antibodies to interferon beta-1a (BAB to IFN beta-1a) in serum using ELISA has been developed.
E. A. Kuzminova, T. Yu. Ostroukhova, A. V. Grachev, E. L. Morozova   +3 more
doaj  

Algorithms in Allergy: Treatment of Hypereosinophilic Syndromes, 2026 Update

Allergy, EarlyView.
Guillaume Lefèvre, Florence Roufosse, Giacomo Emmi, Andreas Reiter, Emmanuel Ledoult, Jean‐Emmanuel Kahn   +5 more
wiley   +1 more source

Phototherapy Strategies for Cancer Treatment: Mechanisms and Emerging Nanomaterials

Aggregate, Volume 7, Issue 10, October 2026.
Phototherapy offers spatiotemporally controlled cancer treatment by converting light into heat, reactive oxygen species, immune activation, and therapeutic gas release. This review summarizes the mechanisms and emerging nanomaterials for photothermal therapy, photodynamic therapy, photoimmunotherapy, and photo‐gas therapy, emphasizing structure ...
Fan Liu, Jun Huang
wiley   +1 more source

Forest plot showing the achievement of SVR in CHC patients with a rapid virological response treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.

, 2014
Forest plot showing the achievement of SVR in CHC patients with a rapid virological response treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.
Caterina Sagnelli (430094), Evangelista Sagnelli (430095), Nicola Coppola (430089), Italo F. Angelillo (300520), Mariantonietta Pisaturo (430090)   +4 more
core   +1 more source

CO‐Rebreathing in Essential Thrombocythemia and Polycythemia Vera. A Revival of an Old Methodology to Improve Diagnosis and Phlebotomy Decisions

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT The diagnostic landscape for the Philadelphia‐negative myeloproliferative neoplasms (MPNs), particularly in distinguishing Essential Thrombocythemia (ET) from Polycythemia Vera (PV), is compromised. The gold standard for diagnosing PV—measurement of red cell mass (RCM) by radioisotope dilution—has been largely abandoned, leading to widespread ...
Hans C. Hasselbalch, Morten Kranker Larsen, Lea Løffler, Camilla Andersen, Isabella Davidsen, Mette Grymer Jensen, Jonas Bechlund, Lasse Kjær, Vibe Skov, Henning Bay Nielsen, Carsten Lundby   +10 more
wiley   +1 more source

Forest plot showing the achievement of SVR in CHC patients with the IL28-B CC haplotype treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.

, 2014
Forest plot showing the achievement of SVR in CHC patients with the IL28-B CC haplotype treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.
Caterina Sagnelli (430094), Evangelista Sagnelli (430095), Nicola Coppola (430089), Italo F. Angelillo (300520), Mariantonietta Pisaturo (430090)   +4 more
core   +1 more source